Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...

IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage study, but narrowly missed the main goal as the results did not show ...